Treating Hallucinations and Delusions Associated With Parkinson's Disease Psychosis

被引：6
作者：
Panchal, Shyam C. [1 ]
Ondo, William G. [1 ]
机构：
[1] Houston Methodist Neurol Inst, Dept Neurol, 6560 Fannin St,Scurlock Tower,Suite 802, Houston, TX 77030 USA
来源：
CURRENT PSYCHIATRY REPORTS | 2018年 / 20卷 / 01期
关键词：
Parkinson's disease; Psychosis; Hallucinations; Delusions; Pimavanserin; Antipsychotic; DRUG-INDUCED PSYCHOSIS; LEVODOPA-INDUCED PSYCHOSIS; VISUAL HALLUCINATIONS; DOUBLE-BLIND; RISK-FACTORS; OLANZAPINE TREATMENT; BEHAVIORAL SYMPTOMS; CLOZAPINE TREATMENT; POSITIVE SYMPTOMS; RATING-SCALE;
D O I：
10.1007/s11920-018-0869-z
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
Purpose of Review We discuss features of Parkinson's disease psychosis (PDP) including symptomology and pathophysiology. Treatment options, including non-pharmacologic strategies, dose reduction of offending agents, and the addition of non-dopaminergic antipsychotics, are addressed. The efficacy of second-generation antipsychotics and novel agents is examined. Recent Findings Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment. Research into novel targets is ongoing. Summary PDP is a morbid complication of Parkinson's disease with complex incompletely understood mechanisms. Treatment is directed towards mitigation of psychosis without worsening of motor features.
引用
收藏
页数：10
相关论文
共 113 条
[1]   Prevalence and clinical correlates of psychotic symptoms in Parkinson disease - A community-based study [J].
Aarsland, D ;
Larsen, JP ;
Cummings, JL ;
Laake, K .
ARCHIVES OF NEUROLOGY, 1999, 56 (05) :595-601
[2]   CLOZAPINE-INDUCED AGRANULOCYTOSIS - INCIDENCE AND RISK-FACTORS IN THE UNITED-STATES [J].
ALVIR, JMJ ;
LIEBERMAN, JA ;
SAFFERMAN, AZ ;
SCHWIMMER, JL ;
SCHAAF, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (03) :162-167
[3]   Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease [J].
Ballanger, Benedicte ;
Strafella, Antonio P. ;
van Eimeren, Thilo ;
Zurowski, Mateusz ;
Rusjan, Pablo M. ;
Houle, Sylvain ;
Fox, Susan H. .
ARCHIVES OF NEUROLOGY, 2010, 67 (04) :416-421
[4]  
Barbato L, 1996, FUNCT NEUROL, V11, P201
[5]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[6]   THE BRIEF PSYCHIATRIC RATING-SCALE (BPRS) IN GEROPSYCHIATRIC RESEARCH .2. REPRESENTATIVE PROFILE PATTERNS [J].
BELLER, SA ;
OVERALL, JE .
JOURNALS OF GERONTOLOGY, 1984, 39 (02) :194-200
[7]   DOPAMINE ACTION AND DISORDERS OF NEUROTRANSMITTER BALANCE [J].
BIRKMAYER, W ;
BIRKMAYER, JD .
GERONTOLOGY, 1987, 33 (3-4) :168-171
[8]   Palliative Care and Parkinson's Disease: Caregiver Perspectives [J].
Boersma, Isabel ;
Jones, Jacqueline ;
Coughlan, Christina ;
Carter, Julie ;
Bekelman, David ;
Miyasaki, Janis ;
Kutner, Jean ;
Kluger, Benzi .
JOURNAL OF PALLIATIVE MEDICINE, 2017, 20 (09) :930-938
[9]  
Bosboom JLW, 2003, J NEURAL TRANSM-SUPP, P185
[10]   Development and evaluation of the Parkinson Psychosis Questionnaire - A screening-instrument for the early diagnosis of drug-induced psychosis in Parkinson's disease [J].
Brandstaedter, D ;
Spieker, S ;
Ulm, G ;
Siebert, U ;
Eichhorn, TE ;
Krieg, JC ;
Oertel, WH ;
Eggert, K .
JOURNAL OF NEUROLOGY, 2005, 252 (09) :1060-1066
12345678910